Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Oppenheimer & Co.
Mark Breidenbach Ph.D.
RBC Capital Markets
Kennen MacKay

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.